Paricalcitol and Extended Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis.
Matteo FranchiJoel GunnarssonEmilio Gonzales-ParraAnibal FerreiraOskar StrömGiovanni CorraoPublished in: The Journal of clinical endocrinology and metabolism (2023)
This NMA showed that ERC is comparable in lowering PTH levels vs PCT. ERC displayed avoidance of potentially clinically relevant increases in serum calcium, offering an effective and well tolerated treatment option for the management of SHPT in patients with ND CKD.